IRWD Quote, Financials, Valuation and Earnings

Akebia Therapeutics, Inc. has a net margin of 32.84% compared to Ironwood Pharmaceuticals, Inc.'s net margin of 0.92%. Ironwood Pharmaceuticals, Inc.'s return on equity of -- beat Akebia Therapeutics, Inc.'s return on equity of --.

Ironwood Pharmaceuticals, Inc. has a consensus price target of $2.50, signalling downside risk potential of -32.98%. On the other hand Akebia Therapeutics, Inc. has an analysts' consensus of $5.40 which suggests that it could grow by 239.62%. Given that Akebia Therapeutics, Inc. has higher upside potential than Ironwood Pharmaceuticals, Inc., analysts believe Akebia Therapeutics, Inc. is more attractive than Ironwood Pharmaceuticals, Inc..

Ironwood Pharmaceuticals, Inc. has a beta of 0.177, which suggesting that the stock is 82.259% less volatile than S&P 500. In comparison Akebia Therapeutics, Inc. has a beta of 0.311, suggesting its less volatile than the S&P 500 by 68.934%.

Ironwood Pharmaceuticals, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Akebia Therapeutics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Ironwood Pharmaceuticals, Inc. pays -- of its earnings as a dividend. Akebia Therapeutics, Inc. pays out -- of its earnings as a dividend.

Ironwood Pharmaceuticals, Inc. quarterly revenues are $122.1M, which are larger than Akebia Therapeutics, Inc. quarterly revenues of $58.8M. Ironwood Pharmaceuticals, Inc.'s net income of $40.1M is higher than Akebia Therapeutics, Inc.'s net income of $540K. Notably, Ironwood Pharmaceuticals, Inc.'s price-to-earnings ratio is 24.14x while Akebia Therapeutics, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Ironwood Pharmaceuticals, Inc. is 1.86x versus 1.78x for Akebia Therapeutics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Puma Biotechnology, Inc. has a net margin of 32.84% compared to Ironwood Pharmaceuticals, Inc.'s net margin of 16.24%. Ironwood Pharmaceuticals, Inc.'s return on equity of -- beat Puma Biotechnology, Inc.'s return on equity of 38.49%.

Ironwood Pharmaceuticals, Inc. has a consensus price target of $2.50, signalling downside risk potential of -32.98%. On the other hand Puma Biotechnology, Inc. has an analysts' consensus of $3.50 which suggests that it could fall by -33.84%. Given that Puma Biotechnology, Inc. has more downside risk than Ironwood Pharmaceuticals, Inc., analysts believe Ironwood Pharmaceuticals, Inc. is more attractive than Puma Biotechnology, Inc..

Ironwood Pharmaceuticals, Inc. has a beta of 0.177, which suggesting that the stock is 82.259% less volatile than S&P 500. In comparison Puma Biotechnology, Inc. has a beta of 1.177, suggesting its more volatile than the S&P 500 by 17.656%.

Ironwood Pharmaceuticals, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Puma Biotechnology, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Ironwood Pharmaceuticals, Inc. pays -- of its earnings as a dividend. Puma Biotechnology, Inc. pays out -- of its earnings as a dividend.

Ironwood Pharmaceuticals, Inc. quarterly revenues are $122.1M, which are larger than Puma Biotechnology, Inc. quarterly revenues of $54.5M. Ironwood Pharmaceuticals, Inc.'s net income of $40.1M is higher than Puma Biotechnology, Inc.'s net income of $8.8M. Notably, Ironwood Pharmaceuticals, Inc.'s price-to-earnings ratio is 24.14x while Puma Biotechnology, Inc.'s PE ratio is 7.14x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Ironwood Pharmaceuticals, Inc. is 1.86x versus 1.25x for Puma Biotechnology, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Pfizer Inc. has a net margin of 32.84% compared to Ironwood Pharmaceuticals, Inc.'s net margin of 21.32%. Ironwood Pharmaceuticals, Inc.'s return on equity of -- beat Pfizer Inc.'s return on equity of 10.84%.

Ironwood Pharmaceuticals, Inc. has a consensus price target of $2.50, signalling downside risk potential of -32.98%. On the other hand Pfizer Inc. has an analysts' consensus of $29.04 which suggests that it could grow by 13%. Given that Pfizer Inc. has higher upside potential than Ironwood Pharmaceuticals, Inc., analysts believe Pfizer Inc. is more attractive than Ironwood Pharmaceuticals, Inc..

Ironwood Pharmaceuticals, Inc. has a beta of 0.177, which suggesting that the stock is 82.259% less volatile than S&P 500. In comparison Pfizer Inc. has a beta of 0.457, suggesting its less volatile than the S&P 500 by 54.271%.

Ironwood Pharmaceuticals, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Pfizer Inc. offers a yield of 6.69% to investors and pays a quarterly dividend of $0.43 per share. Ironwood Pharmaceuticals, Inc. pays -- of its earnings as a dividend. Pfizer Inc. pays out 119.94% of its earnings as a dividend.

Ironwood Pharmaceuticals, Inc. quarterly revenues are $122.1M, which are smaller than Pfizer Inc. quarterly revenues of $16.7B. Ironwood Pharmaceuticals, Inc.'s net income of $40.1M is lower than Pfizer Inc.'s net income of $3.6B. Notably, Ironwood Pharmaceuticals, Inc.'s price-to-earnings ratio is 24.14x while Pfizer Inc.'s PE ratio is 14.98x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Ironwood Pharmaceuticals, Inc. is 1.86x versus 2.34x for Pfizer Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Pyxis Oncology, Inc. has a net margin of 32.84% compared to Ironwood Pharmaceuticals, Inc.'s net margin of -650.85%. Ironwood Pharmaceuticals, Inc.'s return on equity of -- beat Pyxis Oncology, Inc.'s return on equity of -90.91%.

Ironwood Pharmaceuticals, Inc. has a consensus price target of $2.50, signalling downside risk potential of -32.98%. On the other hand Pyxis Oncology, Inc. has an analysts' consensus of $7.68 which suggests that it could grow by 77.66%. Given that Pyxis Oncology, Inc. has higher upside potential than Ironwood Pharmaceuticals, Inc., analysts believe Pyxis Oncology, Inc. is more attractive than Ironwood Pharmaceuticals, Inc..

Ironwood Pharmaceuticals, Inc. has a beta of 0.177, which suggesting that the stock is 82.259% less volatile than S&P 500. In comparison Pyxis Oncology, Inc. has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.

Ironwood Pharmaceuticals, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Pyxis Oncology, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Ironwood Pharmaceuticals, Inc. pays -- of its earnings as a dividend. Pyxis Oncology, Inc. pays out -- of its earnings as a dividend.

Ironwood Pharmaceuticals, Inc. quarterly revenues are $122.1M, which are larger than Pyxis Oncology, Inc. quarterly revenues of --. Ironwood Pharmaceuticals, Inc.'s net income of $40.1M is higher than Pyxis Oncology, Inc.'s net income of -$22M. Notably, Ironwood Pharmaceuticals, Inc.'s price-to-earnings ratio is 24.14x while Pyxis Oncology, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Ironwood Pharmaceuticals, Inc. is 1.86x versus 93.87x for Pyxis Oncology, Inc.. Usually stocks with elevated PS ratios are considered overvalued.